共查询到20条相似文献,搜索用时 15 毫秒
1.
Understanding EGFR Signaling in Breast Cancer and Breast Cancer Stem Cells: Overexpression and Therapeutic Implications 下载免费PDF全文
《Asian Pacific journal of cancer prevention》2016,17(2):445-453
Epidermal growth factor receptors (EGFRs/HERs) and downstream signaling pathways have been implicated in the pathogenesis of several malignancies including breast cancer and its resistance to treatment with chemotherapeutic drugs. Consequently, several monoclonal antibodies as well as small molecule inhibitors targeting these pathways have emerged as therapeutic tools in the recent past. However, studies have shown that utilizing these molecules in combination with chemotherapy has yielded only limited success. This review describes the current understanding of EGFRs/HERs and associated signaling pathways in relation to development of breast cancer and responses to various cancer treatments in the hope of pointing to improved prevention, diagnosis and treatment. Also, we review the role of breast cancer stem cells (BCSCs) in disease and the potential to target these cells. 相似文献
2.
3.
Pingping Guo Wenqi Chen Huiyu Li Meiying Li Lisha Li 《Pathology oncology research : POR》2018,24(4):807-813
The histone acetylation modifications (HAMs) influence a large number of cellular functions. They are mediated through histone acetyltransferase (HAT) and histone deacetylase (HDAC). Nowadays, people have realized that HAMs are crucial for development and prognosis of breast cancer. Investigations about abnormal HAMs in breast cancer focus on initiating molecular mechanisms in breast cancer development, identification of new biomarkers to predict breast cancer aggressiveness and the therapeutic potential. As HAMs are reversible, breast cancer may be treated by restoring HAMs to normal levels. Indeed, some HDAC inhibitors have been approved by the US Food and Drug Administration to treat certain cancers. Furthermore, HAT inhibitors, HAT activators and HDAC activators may also be used as drugs to treat breast cancer. 相似文献
4.
Tone Ikdahl Andersen 《Acta oncologica (Stockholm, Sweden)》1996,35(4):407-410
Approximately 20% of breast cancer patients have a family history of the disease, and in one-fourth of these cases breast cancer appears to be inherited as an autosomally dominant trait. Five genes and gene regions involved in breast cancer susceptibility have been uncovered. Germ-line mutations in the recently cloned BRCA1 gene at 17q21 is considered to be responsible for the disease in a majority of the breast-ovarian cancer families and in 40-45% of the site-specific breast cancer families, but appears not to be involved in families with both male and female breast cancer cases. The BRCA2 locus at 13q12-q13 appears to be involved in 40-45% of the site-specific breast cancer families, and in most of the families with affected males. The gene located in this region, however, does not seem to confer susceptibility to ovarian cancer. The TP53 gene is involved in breast cancer development in the Li-Fraumeni syndrome and Li-Fraumeni syndrom-like families, whereas germ-line mutations in the androgen receptor (AR) gene is present in a subset of male breast cancers. Furthermore, females who are obligate carriers of ataxia telangiectasia (AT) have a 4-12 times relative risk of developing breast cancer as compared with the general female population, indicating that germ-line mutations in AT also confer susceptibility to breast cancer. 相似文献
5.
6.
Intratumoral Heterogeneity in Breast Cancer: A Comparison of Primary and Metastatic Breast Cancers 下载免费PDF全文
Intratumoral heterogeneity presents challenges in the management of cancer. To gain deeper insight in intratumoral heterogeneity at different levels and tumor sites for common biomarkers in breast cancers, this report examines seven cases of invasive breast cancer with multiple axillary nodal metastases and/or recurrences for immunohistochemical expression of estrogen receptors, progesterone receptors, human epidermal growth receptor 2, and Ki67 on all tissue blocks in both primary and metastatic tumors. 相似文献
7.
Triple-negative breast cancers (TNBCs) are a group of aggressive breast cancers with a greater incidence of relapse, stage-for-stage, than ER/PR-positive and HER2-positive breast cancers, despite optimum loco-regional and systemic therapy. To date, no single targeted therapy has been approved for treatment of TNBC, and cytotoxic chemotherapy remains the standard systemic treatment. Recently, gene expression analysis identified six distinct TNBC subtypes, each with unique biology. In this review we discuss current and forthcoming therapeutic strategies and novel approaches to targeted treatment of these TNBC subtypes. 相似文献
8.
Ana Costa Yann Kieffer Alix Scholer-Dahirel Floriane Pelon Brigitte Bourachot Melissa Cardon Philemon Sirven Ilaria Magagna Laetitia Fuhrmann Charles Bernard Claire Bonneau Maria Kondratova Inna Kuperstein Andrei Zinovyev Anne-Marie Givel Maria-Carla Parrini Vassili Soumelis Anne Vincent-Salomon Fatima Mechta-Grigoriou 《Cancer cell》2018,33(3):463-479.e10
9.
10.
11.
12.
Detection of VIP Receptors in MNU-Induced Breast Cancer in Rats: Implications for Breast Cancer Targeting 总被引:1,自引:0,他引:1
Vasoactive intestinal peptide (VIP) is a 28 amino acid neuropeptide with a wide range of biological activities. Receptors for VIP (VIP-R) are overexpressed in breast cancer, where they may have diagnostic and therapeutic implications. Although N-methyl nitrosourea (MNU)-induced breast cancer in rats is used extensively as a model to study mammary carcinogenesis, there is no information about the expression of VIP-R in this model. Therefore, the purpose of this study was to investigate the presence of VIP-R in MNU-induced breast cancer in rats so that this model can be used to perform studies involving VIP-R. Breast cancer was induced in 36-day-old virgin female Sprague-Dawley rats, by a single intravenous injection of MNU (50mg/kg body weight). The breast tumors were detected 100–150 days after injection. The normal and cancerous rat breast tissue were excised and 20 sections were incubated with 40nM fluorescein-labeled VIP (Fluo-VIPTM), in the presence and absence of 1000-fold excess unlabeled VIP, pituitary adenylate cyclase activating polypeptide (PACAP) or secretin. The sections were visualized under a fluorescence microscope and photographed. Fluo-VIPTM stained rat breast cancer tissue homogeneously and to a much greater extent than normal rat breast tissue (p<0.05). This staining was specific as indicated by displacement of Fluo-VIPTM by excess unlabeled VIP and PACAP. Displacement of Fluo-VIPTM by secretin indicated the probable presence of VIP receptors of type VPAC1 (VIP receptor subtype1) in the rat breast. These data suggest that, as in human breast cancer, VIP-R, predominantly of type VPAC1, are overexpressed in MNU-induced rat breast cancer tissue as compared to the normal rat breast tissue. Thus, MNU-induced rat breast cancer model can be used as a tool to study the functional role of VIP-R in human mammary carcinogenesis and VIP-R mediated active breast cancer targeting. This could have implications in the diagnosis, prognosis and therapy of human breast cancer. 相似文献
13.
The hypothesis that cancer is driven by a subpopulation of tumor-initiating or cancer stem cells (CSC), defined by their selective
ability for extensive self-renewal and capacity to give rise to nontumorigenic cancer cell progeny through differentiation,
has been validated experimentally in diverse human malignancies. Translational relevance of the CSC hypothesis is underlined
by emerging novel strategies designed to target all subpopulations within a given tumor in order to effect cancer eradication
and improve patient outcomes. Colorectal cancer stem cells (CRSCs) have been identified and successfully isolated by several
research groups based on distinct cell-surface marker characteristics. Identification of CRSC populations has led to a wave
of discoveries describing novel self-renewal and drug resistance mechanisms in colorectal cancer that represent novel future
therapeutic targets. In this review, we will discuss emerging CRSC-specific pathways and the therapeutic promise of targeting
this cancer population in colorectal cancer patients. 相似文献
14.
15.
Inflammatory breast cancer (IBC) is the most lethal variant of locally advanced breast cancer. Although recognized as a distinct clinical entity, there have been few advances in the development of pre-clinical models of IBC, and a lack of IBC-specific therapeutic targets translated into clinical utility to increase overall survival, which is currently 40?% at three years. By use of newly developed pre-clinical models of IBC and patient tumor tissues, E-cadherin, anaplastic lymphoma kinase (ALK), and HSP90 have been identified as targets relevant to IBC that are matched by therapeutics that are either currently in clinical trials or will be tested in clinical trials within the next year. These exciting results illustrate the advances that have been made in recent years in defining the molecular basis of IBC as a distinct disease and the significant strides made in identifying more effective strategies for treatment of patients with IBC. 相似文献
16.
Fayaz Malik Hasan Korkaya Shawn G. Clouthier Max S. Wicha 《Current breast cancer reports》2012,4(4):225-231
Although the heterogeneity of breast cancer has long been recognized, the hierarchical organization and existence of tumor initiating subpopulation within breast tumors was not known until the last decade. These tumor initiating cells called cancer stem cells (CSCs) display features of stem cells such as unlimited ability to self-renew and lineage differentiation. Accumulating evidence now suggests that by virtue of their relative resistance to both radiation and chemotherapy, these cells contribute to resistance and relapse following therapy. Utilizing cell cultures and mouse xenograft models, we and others demonstrated that breast CSCs have far greater invasive and metastatic potential than differentiated tumor cells which comprise the tumor bulk. Altogether, these studies suggest that targeting and elimination of breast CSCs may be required to improve patient outcome. In this review, we will discuss recent developments in breast CSC research and advances in CSC specific targeted therapies that are in preclinical and clinical trials. 相似文献
17.
Sudeep Gupta Ashish Singh Bharat Singh Bhosale Bhawna Sirohi 《Current breast cancer reports》2013,5(4):275-283
Despite improvements in early detection and adjuvant treatment, a significant fraction of women with early stage breast cancer will eventually develop a recurrence. While improvement in outcomes in metastatic disease has been achieved with new therapeutic options almost all patients eventually develop tumor progression due to drug resistance. We review the mechanisms of resistance to commonly used endocrine, chemotherapeutic, and targeted agents in breast cancer and the interplay of the biomarkers therein. 相似文献
18.
19.
Long Non Coding RNA in Triple Negative Breast Cancer: A Promising Biomarker in Tumorigenesis 下载免费PDF全文
Srividhya NandagopalSanjeev MisraShrimanjunath SankanagoudarMithu BanerjeePraveen SharmaStacey Ellen PaneGiulia GuerrieroKamla Kant Shukla 《Asian Pacific journal of cancer prevention》2023,24(1):49-59
Globally, Triple-negative breast cancer (TNBC) is an unsurpassed variant of breast cancer (BC) with a very high fatality rate, and disease burden. Nevertheless, the deficit of diagnostic markers and focused treatment are major hurdles for potent therapeutics. They are also the reason for bad outcomes and causes of a worse prognosis and a high rate of flare up in patients with TNBC diagnosis. Long non-coding RNAs (lncRNA) are a new class of molecules that have recently gained interest in healthcare management due to their potential as biomarkers for human diseases especially cancers. The growing interest in lncRNA in clinical practice has created an unmet need for developing assays to test lncRNA quickly and accurately for early diagnostics. These lncRNA modulate multiple stages of tumor development, including growth, proliferation, invasion, angiogenesis, and metastases, by controlling several genes and changing metabolic networks. Highly invasive phenotype and chemo resistance are prominent characteristics of TNBC subtypes that require accurate diagnostic and prognostic instruments involving lncRNA. This review focusses on the evolving purpose and coalition of lncRNAs in TNBC and accentuates their capable effects in diagnosis and treatment of cancer. Moreover, the extensive literature analysis of our review creates an opportunity in the translational application concerning the TNBC lncRNAs described until now. The depiction of lncRNAs enrolled in TNBC is comprehensive, and sufficient substantiation studies are the need of the hour to authenticate the current outcomes and create imminent upcoming of elemental research setting into clinical practice. 相似文献
20.
Breast cancer is one of the major public health problems of the Western world. Recent advances in genomics and gene expression‐profiling approaches have enriched our understanding of this heterogeneous disease. However, progress in functional proteomics in breast cancer research has been relatively slow. Allied with genomics, the functional proteomics approach will be important in improving diagnosis through better classification of breast cancer and in predicting prognosis and response to different therapies, including chemotherapy, hormonal therapy, and targeted therapy. In this review, we will present functional proteomic approaches with a focus on the recent clinical implications of utilizing the reverse‐phase protein array platform in breast cancer research. 相似文献